How to Inject Peptides: Sites, Angle and the Units per Dose

This page reports how a subcutaneous peptide injection is done, as the product labels and nursing references describe it, and what the syringe reads for a given dose. It is written from six current US labels, a CDC chapter, an open nursing textbook and one international consensus, each dated. It gives no instruction; the label of the product in hand does that.

A subcutaneous injection places a small volume of liquid into the fat layer between the skin and the muscle. The approved peptide products, the semaglutide, tirzepatide and tesamorelin brands, are all labelled for that route, and their labels, medication guides and instructions for use are the only site-specific documents that exist for any injectable peptide. Research compounds sold as lyophilized vials have no label of their own; what circulates for them is borrowed from these documents. The arithmetic that turns a quantity into a syringe reading is the same for every vial and is worked on the insulin syringe units page and in the site's calculators.

The sites, as the labels list them

All labels read on DailyMed or the manufacturer's prescribing information on 2026-09-18. Two things stand out. The upper-arm restriction on the tirzepatide labels is about reach, since the back of the arm cannot be reached by the injecting hand, and the labels that report exposure by site, OZEMPIC and ZEPBOUND, both state that exposure was similar from the abdomen, thigh and upper arm. The site lists are not absorption findings. Peptifact's peptide injection sites page works through the differences between the labels in detail.

The procedure, as one label describes it

The OZEMPIC prefilled-syringe Instructions for Use (revised June 2026) are the plainest current description of a syringe injection, because the device is a syringe rather than a pen. The steps, in the label's order: inspect the liquid, which is used only if clear and colourless; choose a site, the abdomen at least 2 inches from the belly button, a thigh, or the back of the upper arm with help from someone else, avoiding the exact spot used last time; clean the site with an alcohol wipe and allow it to dry; pinch and hold a fold of skin between thumb and fingers for the whole injection; insert the needle fully into the pinched skin at a 45-degree angle, which the label explains is to inject under the skin and not into muscle; keep the angle and push the plunger all the way down until it stops; pull the syringe out at the same angle; if blood appears, press lightly with a cotton ball or gauze without rubbing. The used syringe goes into a sharps container and the needle cap is not replaced.

The EGRIFTA SV kit adds the vial-and-syringe detail the pen products lack: it ships 20-gauge 1-inch needles for mixing and 30-gauge half-inch needles for injecting, and its label states the 1.4 mg dose as 0.35 mL of the reconstituted solution, injected into the abdomen (label revised 2/2024, read 2026-09-18). The general reconstitution procedure for research vials is Medibact's topic, on its page on how to reconstitute peptides.

Needle, angle and pinch, as nursing references state them

CDC's Pink Book, chapter 6 (reviewed 2024-04-08), gives the subcutaneous vaccine technique: a 5/8-inch (16 mm), 23- to 25-gauge needle, inserted at a 45-degree angle into the fatty tissue above the upper outer triceps for anyone aged one year or older, into the thigh for infants, with the skin and underlying fatty tissue pinched up. It states that aspiration is not recommended and that multiple injection sites are separated by an inch or more so that local reactions can be told apart.

Nursing Skills, 2nd edition (Open RN, CC BY 4.0), lists the outer lateral upper arm, the abdomen from below the costal margin to the iliac crest and more than two inches from the umbilicus, the anterior upper thighs, the upper back and the upper ventral gluteal area. It gives needles of 25 to 31 gauge and half to five-eighths of an inch, a 90-degree angle for normal-sized or obese adults and 45 degrees for thin patients or sites with less fat, the skin grasped and pinched, and no more than 1 mL per subcutaneous injection in adults.

The FITTER recommendations (Frid et al., Mayo Clinic Proceedings 2016, PMID 27594187), the consensus of 183 diabetes experts, state that the shortest needles, currently 4 mm pen and 6 mm syringe needles, are safe, effective, less painful and first-line for all patient categories; that intramuscular injection is to be avoided; and that lipohypertrophy, a frequent complication of repeated injection, distorts absorption and is prevented by correct site rotation. The two angles in the sources are consistent once needle length is added: a 45-degree angle into a pinched fold is the label's way of keeping a longer needle out of muscle, and short needles are what make 90 degrees possible.

Reading the syringe for a dose

A U-100 insulin syringe reads 100 units per millilitre, so one unit is 0.01 mL. The MOUNJARO and ZEPBOUND labels put the reading in label language: vial users are told to use a syringe capable of measuring a 0.5 mL or 0.6 mL dose, which on a U-100 scale is 50 or 60 units, and to use a new syringe and needle each time. For a reconstituted research vial the reading follows from the concentration:

units = quantity in mg ÷ concentration in mg/mL × 100

A 5 mg vial in 2 mL is 2.5 mg/mL; a 10 mg vial in 2 mL is 5 mg/mL; a 1 mg vial in 1 mL is 1 mg/mL. The site's reconstitution calculator returns the reading for every compound it covers, and the syringes page covers which barrel resolves which draw.

Rotation and injection-site reactions

Rotation is in every label above, and one label says why in numbers: EGRIFTA reports injection site reactions, including erythema, pruritus, pain, irritation and bruising, in 25% of treated patients against 14% on placebo during the first 26 weeks of its trials (EGRIFTA WR label, read 2026-09-18). FITTER ties rotation to lipohypertrophy and absorption. CDC ties site separation to telling reactions apart. None of the sources ties rotation to how much drug is absorbed from a healthy site; the exposure statements above say the opposite.

What the labels do not cover

None of the compounds sold as research vials has a label, so none has an approved site, angle, needle or volume, and no figure on this page was measured on those products. The procedure above is what the labelled peptides and the nursing references state, reported so that a reader can see where each convention comes from and what it does not rest on.

Related pages

The insulin syringe units page covers U-100, U-40 and the barrel sizes; the syringes page covers gauge, length and dead space; the reconstitution hub indexes the per-compound water and unit pages; the dosage hub holds the reported ranges by compound.

This page does not instruct anyone to inject anything, and it does not recommend a site, an angle, a needle or a dose. It reports what six labels, a CDC chapter, a nursing textbook and one consensus document state, each with its date, and it does the arithmetic that turns a quantity into a syringe reading.

Sources and dates

Opened 2026-09-18: the OZEMPIC prescribing information (revised 05/2026) with its medication guide and prefilled-syringe Instructions for Use (revised June 2026), from the manufacturer's document; the MOUNJARO prescribing information (revised 08/2026) from the manufacturer's document; the ZEPBOUND label (revised 8/2026, DailyMed setid 487cd7e7-434c-4925-99fa-aa80b1cc776b); the WEGOVY label (revised 6/2026, setid ee06186f-2aa3-4990-a760-757579d8f77b); the EGRIFTA WR label (revised 3/2025, setid 839334d3-8c1d-4c26-9036-2ab524a6ea75) and EGRIFTA SV label (revised 2/2024, setid 3d783378-b02d-4f19-99dd-0fc91a042224); CDC Pink Book chapter 6, Vaccine Administration (reviewed 2024-04-08); Nursing Skills, 2nd edition, chapter 18 (Open RN, NCBI Bookshelf NBK596739); Frid et al. 2016 (PMID 27594187, abstract via the NCBI E-utilities). Corrections go to the contact page.